BNTX

BioNTech SE | Cotação de Ações

Última atualização19/09/2025, 13:13:23

PreçoUS$ 96,57

Variação (dia)US$ 0,26 (0.27%)▲

Min. 52 SemanasUS$ 81,20

Máx. 52 SemanasUS$ 129,27

Capitalização de mercado--

Endereço: An der Goldgrube 12, Mainz, 55131

Telefone: 49 6131 9084

Funcionários: 6.772

BioNTech SEBNTX

US$ 96,57

+ 0,260,27%

19/09/2025 13:13:23

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 96,57

Valor de mercado--

AberturaUS$ 97,88

Preço máximoUS$ 97,84

Preço mínimoUS$ 96,10

VolumeUS$ 283 mil

Fechamento anteriorUS$ 96,31

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Ações relacionadas

Moderna, Inc.

MRNA ▼0.14% | US$ 40,30

Novavax, Inc.

NVAX ▼0.05% | US$ 8,42

AstraZeneca PLC

AZN ▼0.20% | US$ 66,33

Inovio Pharmaceuticals, Inc.

INO ▲0.02% | US$ 1,88

Vaxart, Inc.

VXRT ▲0.13% | US$ 0,74

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.

Descubra as últimas atualizações do mercado de ações, incluindo os preços de empresas como Magazine Luiza (MGLU3) e Petrobras (PETR4)

Mantenha-se informado sobre o mercado de ações com as atualizações da brapi. Em nossa seção de notícias, fornecemos análises profundas sobre empresas líderes, como Magazine Luiza e Petrobras, auxiliando em decisões de investimento mais esclarecidas.